Churchyard, Ph.D., Salome Charalambous, Ph.D., Tag Hatherill, M.D., Hennie Geldenhuys, M.B., Ch.B., Helen M. McIlleron, Ph.D., Simbarashe P. Zvada, M.Phil., Stanley Mungofa, M.P.H., Nasir A. Shah, M.B., B.S., Simukai Zizhou, M.B., Ch.B., Lloyd Magweta, M.B., Ch.B., James Shepherd, Ph.D., Sambayawo Nyirenda, M.D., Janneke H. Van Dijk, Ph.D., Heather E. Clouting, M.Sc., David Coleman, M.Sc., Anna L.E. Bateson, Ph.D., Timothy D. McHugh, Ph.D., Philip D. Butcher, Ph.D., and Denny A.The analysis included 211 head and throat cancers from the oropharynx .23, p < 0.001 for overall survival and disease-specific survival), in comparison to HPV-harmful tumors. Detecting transcriptionally energetic HPV in the tumor cells is crucial to establish its presence as clinically significant, said Dr. James Lewis Jr. Of Washington University in St. Louis, the principal investigator in this collaborative study. Lewis. The incidences of HPV-connected head and throat cancers are increasing quickly in the US and worldwide, and the clinical community has been searching for a robust, definitive HPV test, said Dr.